The National Heart, Lung, and Blood Institute (NHLBI) recently awarded The Texas Heart Institute (THI) a two-year, $1.14 million grant to develop a novel, first-in-class drug to treat cardiovascular disease (CVD) as a significant improvement to current treatment regimens -; specifically for adverse events arising from atherosclerosis.
Stopping High-Efficacy MS Drugs Raises Relapse Risk for Older Patients
Patients ages 50 or older with non-active multiple sclerosis (MS) who discontinued high-efficacy therapy (HET) had a higher risk of relapse compared with those who
March 28, 2024